Dermatology Medical News about psoriasis

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Cost-effectiveness of biologics for moderate-to-severe psoriasis from the perspective of the Swiss healthcare system
European Journal of Dermatology, 09/09/09

Greiner RA et al. – Modeling treatment changes at 12 weeks over 36–weeks–horizon resulted in lowest ICER per PASI 75 responder for adalimumab and infliximab compared to the other biologics. Hence in Switzerland, selecting the initial biologic with a high response rate evidenced best value for money.

<< Previous
Inducible Nitric Oxide Synthase Downmodulates Contact...

Next >>
The epidemiological and clinical presentation of syphilis in a...